Cannabinoid Receptors: A Novel Target for Treating Prostate Cancer

: Prostate Cancer (PC) is one the most prominent cause of deaths in males worldwide especially in western countries. The exhaustive research into prostate cancer to date has demonstrated ELAC2, RNASEL, MSR1, NBS1, CHEK2, MYC, BCL-2, c-Kit, tumor suppressor genes, BRCA1, BRCA2, PACE4, GSTP1, PTEN,CDKN1B, NKX3.1, KLF6, FOXA1, Retinoblastoma, p53, androgen receptor, kallikreins, ETS, CYP17, SRD5A2, E-cadherin, KAI1/CD82, hepsin, AMACR, PIM1, MTA-1, EZH2, EPHB2, growth factors & its receptors, cannabinoid receptors, annexins, oxidative stress and inflammation are entailed changes underlying the initiation, development, and progression of PC. Furthermore, oncology would shift from a reactive to proactive discipline so exploring these targets open new area of research. Therefore, the present review is focused on molecular pathophysiology biomarkers for the progression of PC that would encourage the researchers and pharmaceutical industries to investigate potential therapeutic strategy to overcome demerits of currently available clinically therapies.

Download Full-text

LINC01006 facilitates cell proliferation, migration and invasion in prostate cancer through targeting miR-34a-5p to up-regulate DAAM1

Cancer Cell International ◽

10.1186/s12935-020-01577-1 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Enhui Ma ◽

Qianqian Wang ◽

Jinhua Li ◽

Xinqi Zhang ◽

Zhenjia Guo ◽

...

Keyword(s):

Prostate Cancer ◽

Prostate Gland ◽

Inhibitory Effect ◽

Luciferase Reporter ◽

Migration And Invasion ◽

Protein Coding ◽

Novel Target

Abstract Background Prostate cancer (PCa) is a kind of malignancy occurring in the prostate gland. Substantial researches have proved the major role of long noncoding RNAs (lncRNAs) in PCa. However, the role of long intergenic non-protein coding RNA 1006 (LINC01006) in PCa has not been investigated yet. Methods RT-qPCR was used to examine the expression levels of LINC01006 and its downstream targets. The function of LINC01006 in PCa was tested by in vitro and in vivo assays. With application of RNA pull down, RNA immunoprecipitation (RIP) and luciferase reporter assays, the interaction among LINC01006, miR-34a-5p and disheveled associated activator of morphogenesis 1 (DAAM1) were verified. Results LINC01006 expression presented high in PCa cell lines. LINC01006 silencing suppressed cell proliferative, migratory, invasive capacities while accelerated apoptotic rate. Besides, LINC01006 knockdown also suppressed tumor growth and metastasis in vivo. Furthermore, miR-34a-5p, a tumor suppressor in PCa, was sponged by LINC01006. Moreover, DAAM1 was targeted by miR-34a-5p and promoted PCa progression. More intriguingly, rescue assays suggested that the inhibitory effect of LINC01006 knockdown on PCa development was offset by DAAM1 overexpression. Conclusions LINC01006 promoted PCa progression by sponging miR-34a-5p to up-regulate DAAM1, providing a novel target for PCa therapy.

Download Full-text

Abstract 831: c-Myc is a novel target of prostate cancer cell growth inhibition by honokiol

10.1158/1538-7445.am2016-831 ◽

2016 ◽

Author(s):

Krishna B. Singh ◽

Eun-Ryeong Hahm ◽

Shivendra V. Singh

Keyword(s):

Prostate Cancer ◽

Cell Growth ◽

Growth Inhibition ◽

Cancer Cell ◽

Prostate Cancer Cell ◽

Cell Growth Inhibition ◽

Cancer Cell Growth ◽

Novel Target

Download Full-text

Treatment with Cannabinoids as a Promising Approach for Impairing Fibroblast Activation and Prostate Cancer Progression

International Journal of Molecular Sciences ◽

10.3390/ijms21030787 ◽

2020 ◽

Vol 21 (3) ◽

pp. 787 ◽

Cited By ~ 1

Author(s):

Pietrovito ◽

Iozzo ◽

Bacci ◽

Giannoni ◽

Chiarugi

Keyword(s):

Prostate Cancer ◽

Cancer Cells ◽

Cancer Progression ◽

Stromal Cells ◽

Cannabinoid Receptors ◽

Smooth Muscle Actin ◽

Prostate Tumor ◽

Autocrine Loop ◽

Stromal Component ◽

Win 55

Endo-, phyto- and synthetic cannabinoids have been proposed as promising anti-cancer agents able to impair cancer cells’ behavior without affecting their non-transformed counterparts. However, cancer outcome depends not only on cancer cells’ activity, but also on the stromal cells, which coevolve with cancer cells to sustain tumor progression. Here, we show for the first time that cannabinoid treatment impairs the activation and the reactivity of cancer-associated fibroblasts (CAFs), the most represented stromal component of prostate tumor microenvironment. Using prostate cancer-derived CAFs, we demonstrated that WIN 55-212.2 mesylate, a synthetic full agonist of cannabinoid receptors (CBs) 1 and 2, downregulates α-smooth muscle actin and matrix metalloprotease-2 expression, and it inhibits CAF migration, essential features to ensure the activated and reactive CAF phenotype. Furthermore, by impairing stromal reactivity, WIN 55-212.2 mesylate also negatively affects CAF-mediated cancer cells’ invasiveness. Using selective antagonists of CBs, we proved that CAFs response to WIN 55-212.2 mesylate is mainly mediated by CB2. Finally, we suggest that endocannabinoids self-sustain both prostate tumor cells migration and CAFs phenotype by an autocrine loop. Overall, our data strongly support the use of cannabinoids as anti-tumor agents in prostate cancer, since they are able to simultaneously strike both cancer and stromal cells.

Download Full-text